Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Genitourinary 2Breast 2Gastrointestinal 1Classical hematology 1

Conditions

Metastatic Castration-resistant Prostate Cancer 2

Interventions

pembrolizumab 8Sunitinib 7enfortumab vedotin 6Abiraterone Acetate 6enzalutamide 5Nivolumab 5Gemcitabine 5Cisplatin 5Carboplatin 4avelumab 3Prednisone 3Ipilimumab 3Docetaxel 3Androgen Antagonists 3sacituzumab govitecan 2olaparib 2niraparib 2erdafitinib 2entrectinib 2durvalumab 2darolutamide 2cabozantinib 2belzutifan 2apalutamide 2Pluvicto 2Mitomycin 2Leuprolide 2Everolimus 2Axitinib 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × olaparib × Genitourinary × Clear all
NCT03732820 2026-06-02

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Phase 3 Active not recruiting
895 enrolled 19 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca

Phase 3 Completed
387 enrolled 16 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡